Dengue Virus Type 2 Vaccine: Reactogenicity and Immunogenicity in Soldiers

A live dengue virus type 2 (dengue-2) vaccine (PR-159/S-1)was tested for reactogenicity and immunogenicity in a placebo-controlled, double-blind clinical trial involving 98 soldiers. Seroconversion rates based on the development of neutralizing antibody to dengue-2 were 90% in 70 recipients with imm...

Full description

Saved in:
Bibliographic Details
Published in:The Journal of infectious diseases 1984-06, Vol.149 (6), p.1005-1010
Main Authors: Bancroft, W. H., Scott, R. McN, Eckels, K. H., Hoke, C. H., Simms, T. E., Jesrani, K. D. T., Summers, P. L., Dubois, D. R., Tsoulos, D., Russell, P. K.
Format: Article
Language:English
Subjects:
Adolescent
Adult
Antibodies
Antibodies, Viral - analysis
Antibodies, Viral - biosynthesis
Clinical Trials as Topic
Dengue
Dengue virus
Dengue Virus - immunology
Dengue Virus - isolation & purification
Dengue virus 2
Double-Blind Method
Hemagglutination Inhibition Tests
Humans
Immunization
Infections
Leukocyte Count
Male
Middle Aged
Military Medicine
Neutralization Tests
Neutralizing antibodies
Original Articles
Placebos
Vaccination
Vaccines, Attenuated - immunology
Viral Vaccines - adverse effects
Viral Vaccines - immunology
Viruses
Yellow fever virus
Yellow fever virus - immunology
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:A live dengue virus type 2 (dengue-2) vaccine (PR-159/S-1)was tested for reactogenicity and immunogenicity in a placebo-controlled, double-blind clinical trial involving 98 soldiers. Seroconversion rates based on the development of neutralizing antibody to dengue-2 were 90% in 70 recipients with immunity to yellow fever and 61% in 28 vaccinees without such immunity (P < .01). Peak titers of neutralizing antibody were three times higher in recipients with antibody to yellow fever virus and persisted in most for at least 18 months. Individuals seroconverting to the vaccine virus more frequently experienced systemic symptoms than those who received placebo (P < .02). Future users of this dengue-2 vaccine may wish to employ immunization schedules that include preliminary immunization against yellow fever and must be prepared to accept mild vaccine- related symptoms in some recipients.
ISSN:0022-1899
1537-6613
DOI:10.1093/infdis/149.6.1005